Clinical Scorecard: Assessing the Frequency and Clinical Significance of Carotid Plaque Load via Doppler Ultrasound in Participants Undergoing Lung Cancer Screening with Minimal Coronary Artery Calcification

At a Glance

Key Highlights

• Coronary artery calcium (CAC) scoring via low-dose CT is a strong predictor of coronary artery disease but absence of CAC does not exclude cardiovascular risk.
• Carotid Doppler ultrasound (CDU) detects calcified and non-calcified carotid plaques, providing additional cardiovascular risk stratification especially in subjects with absent or limited CAC.
• Identification of carotid plaques may influence lipid-lowering therapy initiation and improve cardiovascular risk management in lung cancer screening participants.

Guideline-Based Recommendations

Diagnosis

• Use ultra-low dose CT (ULDCT) with AI-driven software to quantify coronary artery calcium (CAC) using Agatston scoring.
• Perform carotid Doppler ultrasound (CDU) to detect and characterize carotid plaques, measuring intima-media thickness and degree of stenosis.
• Consider plaques as structures with intima-media thickness >1.5 mm or >50% increase compared to adjacent segments.

Management

• In participants with absent or limited CAC and no ongoing lipid-lowering therapy, implement CDU evaluation to identify subclinical atherosclerosis.
• Use carotid plaque detection as a modifier for cardiovascular risk stratification to guide initiation of lipid-lowering therapy.
• Integrate CDU findings within a comprehensive cardiovascular risk assessment framework in lung cancer screening programs.

Monitoring & Follow-up

• Regularly assess cardiovascular risk factors including smoking history, hypertension, diabetes, dyslipidemia, and family history.
• Monitor carotid plaque progression and stenosis severity via follow-up CDU as clinically indicated.
• Evaluate treatment response and adherence to lipid-lowering therapy in participants identified at increased cardiovascular risk.

Risks

• Absence of CAC does not imply no cardiovascular risk; subclinical atherosclerosis may still be present.
• Carotid plaques are associated with increased risk of cerebrovascular events, which have been reported in lung cancer screening cohorts.
• Failure to identify subclinical carotid plaques may delay initiation of preventive cardiovascular therapies.

Patient & Prescribing Data

Lung cancer screening participants aged 50–75 years, current or former smokers with ≥15–20 pack-years, with absent or limited coronary artery calcification.

Carotid plaque detection via CDU can support therapeutic decisions, particularly initiation of lipid-lowering therapy, enhancing cardiovascular risk management beyond CAC scoring.

Clinical Best Practices

• Incorporate carotid Doppler ultrasound into cardiovascular risk assessment for lung cancer screening participants with low or absent CAC.
• Use standardized imaging protocols and experienced radiologists for CDU to ensure accurate plaque detection and characterization.
• Apply AI-assisted CAC quantification on ultra-low dose CT scans to improve risk stratification accuracy.
• Consider comprehensive cardiovascular risk factor evaluation alongside imaging findings to guide preventive interventions.

References

• Cardiovascular disease overview and risk factors
• Lung cancer screening and coronary artery calcium scoring
• Carotid plaque detection and cardiovascular risk stratification
• Agatston score and coronary artery calcium risk categories
• European Carotid Surgery Trial (ECST) criteria for stenosis